ProCE Banner Activity

CME

Biomarker Testing in Prostate Cancer: An Essential Component in Transforming Care

Text Module

In this module, a medical oncologist and pathologist discuss how to test for actionable mutations and leverage testing results to individualize PARP inhibitor–based therapy for patients with metastatic prostate cancer.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 22, 2024

Expiration: March 21, 2025

Share

Faculty

Himisha Beltran

Himisha Beltran, MD

Associate Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts 

Steven Christopher Smith

Steven Christopher Smith, MD, PhD

Associate Professor of Pathology and Surgery
Director, Genitourinary and Soft Tissue Pathology
VCU School of Medicine and Massey Comprehensive Cancer Center
Richmond, Virginia

Provided by

Provided by Clinical Care Options, LLC in partnership with the American Society for Clinical Pathology

ProCE Banner

Supporters

Supported by an educational grant from Pfizer, Inc.

Pfizer, Inc.

Partners

American Society for Clinical Pathology

ProCE Banner

Target Audience

This program is intended for oncologists, pathologists, urologists, laboratory professionals, and other HCPs who care for patients with prostate cancer that harbors HRR mutations.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Prostate Cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement strategies to effectively test for HRR mutations based on expert guidance on timing and testing methodologies from blood or tissue

  • Apply multidisciplinary care team communication and workflow strategies for pathological reporting of HRR mutations, considering the implications of misdiagnosis or suboptimal treatment regimens

  • Plan individualized, evidence-based treatment strategies for patients harboring HRR mutations in metastatic prostate cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Himisha Beltran, MD

Associate Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts 

Himisha Beltran, MD: consultant/advisor/speaker: Amgen, Bayer, Janssen, Merck, Pfizer, Roche; researcher: Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo, Novartis.

Steven Christopher Smith, MD, PhD

Associate Professor of Pathology and Surgery
Director, Genitourinary and Soft Tissue Pathology
VCU School of Medicine and Massey Comprehensive Cancer Center
Richmond, Virginia

Steven Christopher Smith, MD, PhD, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC and the American Society for Clinical Pathology do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 22, 2024, through March 21, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.